

19 DEC 2001

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet Of

correction of information divises it on beauty	Valu Corto aprillos immocr.
Application Number I U	7019221
Filing Date	December 19, 2001
First Named Inventor	Masur et al
Group Art Unit	/647
Examiner Name	HAYES
Attorney Docket Number	JAB-1512

				U.S. PATENT DOCUMENTS		
Examiner	Cite	U.S. Patent Document Kind Code ^x		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages
tnitials	No.1	Number	(if known)	or ones boarnen.	mm-dd-yyyy	or relevant figures appear
··						
						
	 					
	 					
		<u> </u>				
					 	
	1		FORE	IGN PATENT DOCUMENTS		

no copy

- 11	,		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
	Examiner Initials	Cite No.1	0.5-3	Number ⁴ KindCode ⁵		Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	™
			VMC - 04/02567		-11	A1 Janssen Pharmaceutice, NV	11/01/2001		
RCH	BEN		wo	99/14235	A1	Washington University	25/03/1999		
		wo	00/05373	A2	Millenium Pharmaceuticals, Inc.	03/02/2000		<u> </u>	
			wo	99/50298	A1	Millennium Pharmaceuticals, Inc	07/10/1999		
l	1		wo	97/33912	A2	Generitech, Inc.	18/09/1997		<u> </u>
I								·	<u> </u>

Examiner Signature	Date Considered	2/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant Is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark. Office. Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patient and Trademant Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displace a walf OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of Sheet

a collection of minimation unless it displays a	With Charles Interior —
Application Number	0/01955/
Filing Date	December 19, 2001
First Named Inventor	Masure et al
Group Art Unit	1647
Examiner Name	HAYES
Attorney Docket Number	JAB-1512
-	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
RON		JANE THOMPSON, EPAMINONDAS DOXAKIS, LUZIA G.P. PINON, PHILIP STRACHAN, ANNA BUJ- BELLO, SEAN WYATT, VLADIMIR L. BUCHMAN, AND ALUN M. DAVIES, "GFRα-4, a New GDNF Family Receptor", Mol. Cell. Neudrosci. 11, 117-126(1998)	
		YASUSHI ENOKIDO, FRED DE SAUVAGE, JO-ANNE HONG, NATALIA NINKINA, ARNON ROSENTHAL, VLADIMIR L. BUCHMAN AND ALUN M. DAVIES, "GRFo-4 and the tyrosine kinase Ret form a functional receptor complex for persephin", Current Biology 8, 1019-1022 (1998)	
		MART SAARMA, HANNU SARIOLA, "Other Neurotrophic Factors: Glial Cell Line-Derived Neurotrophic Factor (GDNF)". Microscopy Research and Technique. 45:292-302(1999)	
		TERESA M. GUNN, KIMBERLY A. MILLER, LIN HE, RICHARD W. HYMAN, RONALD W. DAVIS, AREZOU AZARANI, STUART F. SCHLOSSMAN, JONATHAN S. DUKE-COHAN, GREGORY S. BARSH, "The mouse mahormany locus encodes a tansmembrane form of human attractin", Nature Vol. 398, 152-156(1999).	
		MARIA DE FATIMA BONALDO, GREGORY LENNON, AND MARCELO BENTO SOARES, "Normalization and Subtraction: Two Approaches to Facilitate Gene Discovery", Genome Research, 6:791-806 (1996)	
		MARIA LINDAHL, TONIS TIMMUSK, JARI ROSSI, MART SAARMA, MATTI S.AIRAKSINEN, "Expression and Alternative Splicing of Mouse Gfra4 Suggest Roles in Endocrine Cell Development", Molecular and Cellular Neuroscience 15, 522-533(2000)	
		STEFAN MASURE, MIROSLAV CIK, EVERT HOEFNAGEL, CHRISTOPHER A. NOSRAT, ILSE VAN DER LINDEN, RIZALDY SCOTT, PAUL VAN GOMPEL, ANNE S. J. LESAGE, PETER VERHASSELT, CARLOS F. IBANEZ, ROBERT D.GORDON, "Mammalian GFRa-4, a divergent member of the GFRa family of coresceptors for GDNF family ligands, is a receptor for the neurotrophic factor persephin", American Society	
) —	<u> </u>	for Biochemistry and Molecular Biology, Inc., 1-36 (2000). MATTI S. AIRAKSINEN, ALEXEY TITLEVSKKY, MART SAARMA, "GDNF Earnily Neurotrophic Factor Signaling: Four Masters, One Servant?, Molecular and Cellular Neuroscience 13, 313-325 (1999).	
	7	EMBL DataBase Entry ID No. MMU276872 - 5/1/2000 - EMBL DataBase Entry ID No. AF253318 - 10/26/2000	
1	/-	EMBL DataBase Entry ID No: AW528607 - 3/8/2000	
1 Dett	-	EMBL DataBase Entry ID No. AU035938 - 10/8/1998 - 4 EMBL DataBase Entry ID No. AA823200 - 2/18/1998 - 4	
	7	EMBL DataBase Entry ID No. AE155960 7/28/1999	
~			
			_
	<u> </u>		
			1
			+

Examiner Signature	Ker .	Date Considered	2/10/05	
0.3.00.0				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231:

^{*}EXAMINER: thitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.